{"id":57408,"date":"2023-05-16T08:03:08","date_gmt":"2023-05-16T06:03:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/"},"modified":"2023-05-16T08:03:08","modified_gmt":"2023-05-16T06:03:08","slug":"poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/","title":{"rendered":"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023"},"content":{"rendered":"<div>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg\"><\/a><\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=53400819&amp;newsitemid=20230515005839&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=45b8eab17e243040388253ed4d59ca1b\" rel=\"nofollow noopener\" shape=\"rect\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at 9 am CEST at the Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France.<\/p>\n<p>\nThe meeting notice, the convening brochure, the 2022 Universal Registration Document and the other documents and information mentioned in Article R.22-10-23 of the French Commercial code will be available to shareholders on the Company\u2019s website at least 21 days before the Meeting at the following link: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.poxelpharma.com%2Fen_us%2Finvestors%2Fshareholder-information%2Fannual-general-meeting-documents&amp;esheet=53400819&amp;newsitemid=20230515005839&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.poxelpharma.com%2Fen_us%2Finvestors%2Fshareholder-information%2Fannual-general-meeting-documents&amp;index=2&amp;md5=b4ffde5d93802d0ecccd3889ff67eb72\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/www.poxelpharma.com\/en_us\/investors\/shareholder-information\/annual-general-meeting-documents<\/a><\/p>\n<p>\nShareholders may vote in person on the day of the Meeting, but may also vote by mail or by proxy without attending the Meeting in person, as follows:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nby mail using the voting form; or<\/li>\n<li>\nby giving proxy to the Chairman of the General Meeting or to any other individual or legal entity.<\/li>\n<\/ul>\n<p>\nThe detailed procedures for participating remotely and sending written questions beforehand are available in the meeting notice n\u00b058, which was published in the BALO (French legal gazette) dated May 15, 2023.<\/p>\n<p>\nThe results and presentation for the 2023 Annual General Meeting will be available on Poxel\u2019s website <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=53400819&amp;newsitemid=20230515005839&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=3&amp;md5=4d122b708433d6280629df37e4f4ef7e\" rel=\"nofollow noopener\" shape=\"rect\">www.poxelpharma.com<\/a> in the Investors\/ Shareholder Information\/ Annual General Meeting Documents section after the Meeting.<\/p>\n<p>\n<b>About Poxel SA<\/b><\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical company<\/b> developing <b>innovative treatments for chronic serious diseases with metabolic pathophysiology<\/b>, including <b>non-alcoholic steatohepatitis (NASH)<\/b> and rare disorders. For the treatment of NASH, <b>PXL065<\/b> (deuterium-stabilized <i>R<\/i>-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of <b>PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan, China, and eleven other Asian countries. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=53400819&amp;newsitemid=20230515005839&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=4&amp;md5=70b9865602ef7e03d1bfb0d398eac1a2\" rel=\"nofollow noopener\" shape=\"rect\">www.poxelpharma.com<\/a><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Contacts &#8211; Investor relations \/ Media<\/b><\/p>\n<p>\nAur\u00e9lie Bozza<br \/>\n<br \/>Investor Relations &amp; Communication Senior Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x61;&#117;re&#x6c;&#x69;&#101;&#46;b&#x6f;&#x7a;&#x7a;&#97;&#64;p&#x6f;&#x78;&#101;&#108;p&#x68;&#x61;&#x72;&#109;a&#46;&#x63;&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#97;u&#x72;e&#x6c;i&#x65;&#46;&#x62;&#111;&#x7a;&#122;a&#x40;p&#x6f;x&#x65;&#108;&#x70;&#104;&#x61;&#114;&#x6d;&#97;&#46;&#x63;o&#x6d;<\/a><br \/>+33 6 99 81 08 36<\/p>\n<p>\nElizabeth Woo<br \/>\n<br \/>Senior Vice President, Investor Relations &amp; Communication<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#101;l&#x69;&#122;a&#x62;&#101;t&#x68;&#x2e;w&#x6f;&#x6f;&#64;&#x70;&#x6f;&#120;&#x65;&#x6c;&#112;h&#x61;&#114;m&#x61;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">e&#108;&#105;&#122;&#x61;&#x62;&#x65;th&#46;&#119;&#x6f;&#x6f;&#x40;&#x70;ox&#101;&#108;&#x70;&#x68;&#x61;&#x72;m&#97;&#46;&#99;&#x6f;&#x6d;<\/a><\/p>\n<p>\nNewCap<br \/>\n<br \/>Emmanuel Huynh or Arthur Rouill\u00e9<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;p&#x6f;x&#x65;l&#x40;&#110;&#x65;&#119;&#x63;&#97;&#x70;&#46;&#x65;&#117;\" rel=\"nofollow noopener\" shape=\"rect\">po&#120;&#101;&#108;&#64;&#x6e;&#x65;&#x77;&#x63;&#x61;p&#46;&#101;&#117;<\/a><br \/>+33 1 44 71 94 94<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57408","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-16T06:03:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023\",\"datePublished\":\"2023-05-16T06:03:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/\"},\"wordCount\":446,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230515005839\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/\",\"name\":\"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230515005839\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\",\"datePublished\":\"2023-05-16T06:03:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230515005839\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230515005839\\\/en\\\/729490\\\/21\\\/POXEL_LOGO_Q.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023 - Pharma Trend","og_description":"LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News: POXEL SA (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces the publication of the meeting notice for the Annual General Meeting, which will be held on June 21, 2023 at ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-05-16T06:03:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023","datePublished":"2023-05-16T06:03:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/"},"wordCount":446,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/","url":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/","name":"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg","datePublished":"2023-05-16T06:03:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230515005839\/en\/729490\/21\/POXEL_LOGO_Q.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-announces-notice-of-its-annual-general-meeting-to-be-held-on-june-21-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57408","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57408"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57408\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57408"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57408"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57408"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}